GT Biopharma (GTBP) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01Our financial condition raises substantial doubt as to our ability to continue as a going concern
2. 02Our business is at an early stage of development and we may not develop therapeutic products that can be commercialized
3. 03We have a history of operating losses and we expect to continue to incur losses for the foreseeable future and we may never generate revenue or achieve profitability
4. 04We will need additional capital to conduct our operations and develop our products, and our ability to obtain the necessary funding is uncertain
5. 05Our research and development costs could exceed our projections requiring us to significantly modify our planned operations
6. 06Our intellectual property may be compromised
7. 07If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market and our business would be harmed
8. 08Claims that we infringe the intellectual property rights of others may prevent or delay our drug discovery and development efforts
9. 09We may desire, or be forced, to seek additional licenses to use intellectual property owned by third parties, and such licenses may not be available on commercially reasonable terms or at all
10. 10The patent protection covering some of our product candidates may be dependent on third parties, who may not effectively maintain that protection
11. 11We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful
12. 12If we are unsuccessful in obtaining or maintaining patent protection for intellectual property in development, our business and competitive position would be harmed
13. 13If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
14. 14If we fail to meet our obligations under our license agreements, we may lose our rights to key technologies on which our business depends
15. 15We will have to hire additional employees to carry on our business operations. If we are unable to hire qualified personnel, we may not be able to implement our business strategy
16. 16We depend on key personnel for our continued operations and future success, and a loss of certain key personnel could significantly hinder our ability to move forward with our business plan
17. 17We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property
18. 18Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause our business to suffer
19. 19Our reliance on the activities of our non-employee consultants, research institutions and scientific contractors, whose activities are not wholly within our control, may lead to delays in development of our proposed products
20. 20It may take longer to complete our clinical trials than we project, or we may not be able to complete them at all
21. 21Clinical drug development is costly, time-consuming and uncertain, and we may suffer setbacks in our clinical development program that could harm our business
22. 22If we experience delays or difficulties in the enrollment of patients in clinical trials, those clinical trials could take longer than expected to complete and our receipt of necessary regulatory approvals could be delayed or prevented
23. 23We are subject to extensive regulation, which can be costly and time consuming and can subject us to unanticipated delays. even if we obtain regulatory approval for some of our products, those products may still face regulatory difficulties
24. 24Obtaining regulatory approval even after clinical trials that are believed to be successful is an uncertain process
25. 25We will continue to be subject to extensive FDA regulation following any product approvals, and if we fail to comply with these regulations, we may suffer a significant setback in our business
26. 26The occurrence of any of these actions would likely cause a material adverse effect on our business, financial condition and results of operations
27. 27Laws impacting the U.S. healthcare system are subject to a great deal of uncertainty, which may result in adverse consequences to our business
28. 28We may not be successful in our efforts to build a pipeline of product candidates
29. 29Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any
30. 30We may expend our limited resources to pursue a particular product candidate or indication that does not produce any commercially viable products and may fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
31. 31Our products may be expensive to manufacture, and they may not be profitable if we are unable to control the costs to manufacture them
32. 32The interruption of the flow of raw materials could disrupt the supply chain and our ability to manufacture our products
33. 33We currently lack manufacturing capabilities to produce our therapeutic product candidates at commercial-scale quantities and do not have an alternate manufacturing supply, which could negatively impact our ability to meet any future demand for the product
34. 34To be successful, our proposed products must be accepted by the healthcare community, which can be very slow to adopt or unreceptive to new technologies and products
35. 35Our business is based on novel technologies that are inherently expensive and risky and may not be understood by or accepted in the marketplace, which could adversely affect our future value
36. 36Our competition includes fully integrated biotechnology and pharmaceutical companies that have significant advantages over us
37. 37If competitors develop and market products that are more effective, safer or less expensive than our product candidates or offer other advantages, our commercial prospects will be limited
38. 38If we are unable to keep up with rapid technological changes in our field or compete effectively, we will be unable to operate profitably
39. 39We may not be able to obtain third-party patient reimbursement or favorable product pricing, which would reduce our ability to operate profitably
40. 40We may be subject to litigation that will be costly to defend or pursue and uncertain in its outcome
41. 41We are exposed to the risk of liability claims, for which we may not have adequate insurance
42. 42Our business and operations would suffer in the event of system failures
43. 43We face risks associated with security breaches or cyber-attacks
44. 44Our operations are vulnerable to interruption by natural disasters, power loss, terrorist activity and other events beyond our control, the occurrence of which could materially harm our business
45. 45Epidemic or pandemic outbreaks such as COVID-19 (coronavirus), natural disasters, whether or not caused by climate change, unusual weather conditions, terrorist acts and political events, could disrupt business and result in halting our clinical trials and otherwise adversely affect our financial performance

Risks Related to Our Common Stock

1. 46There has been a limited public market for our common stock , and we do not know whether one will develop to provide adequate liquidity. Furthermore, the trading price for our common stock, should an active trading market develop, may be volatile and could be subject to wide fluctuations in per-share price
2. 47Our outstanding warrants and options may affect the market price of our common stock
3. 48Because our common stock may be deemed a low-priced “penny” stock, an investment in our common stock should be considered high-risk and subject to marketability restrictions
4. 49Financial Industry Regulatory Authority (“FINRA”) sales practice requirements may also limit a stockholder’s ability to buy and sell our common stock, which could depress the price of our common stock
5. 50If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline
6. 51Anti-takeover provisions may limit the ability of another party to acquire us, which could cause our stock price to decline
7. 52We do not currently or for the foreseeable future intend to pay dividends on our common stock
8. 53Our management will have broad discretion as to the use of the proceeds from securities offerings, and may not use the proceeds effectively
9. 54On November 21, 2024, the Company received a letter from Nasdaq notifying the Company that its amount of stockholders’ equity has fallen below the $2,500,000 required minimum for continued listing set forth in Nasdaq Listing Rule 5550(b)(1)